Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05438563

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Mayo Clinic · Academic / Other
Sex
Male
Age
45 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultrasound device guided by MRI imaging to deliver high-energy sound waves, producing very high temperature to ablate (destroy) tumor cells in a targeted manner. The MRI-guided TULSA procedure may help patients avoid surgery and help improve prostate cancer patients' quality of life.

Detailed description

PRIMARY OBJECTIVE: I. To perform the TULSA procedure for safety and efficacy outcomes in men aged 45 to 80 years with biopsy-confirmed, National Comprehensive Cancer Network (NCCN) low to intermediate-risk prostate cancer. SECONDARY OBJECTIVE: I. To assess patient-reported metrics for quality of life (QOL). II. To assess return to normal activity. III. Compare economic benefit as noted from Expanded Prostate Cancer Index Composite (EPIC) questionnaire. OUTLINE: Patients undergo MRI-guided TULSA. Patients may also undergo digital rectal exam (DRE), cystoscopy, biopsy, bone scan, prostate specific membrane antigen (PSMA) positron emission tomography (PET), and/or multiparametric MRI (mpMRI) at screening. After completion of study treatment, patients are followed at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREMRI-Guided Transurethral Ultrasound AblationUndergo MRI-Guided TULSA
OTHERQuestionnaire AdministrationAncillary studies
PROCEDUREDigital Rectal ExaminationUndergo DRE
PROCEDURECystoscopyUndergo cystoscopy
PROCEDUREBiopsyUndergo biopsy
PROCEDUREBone ScanUndergo bone scan
PROCEDUREPSMA PET ScanUndergo PSMA PET
PROCEDUREMultiparametric Magnetic Resonance ImagingUndergo mpMRI

Timeline

Start date
2022-04-06
Primary completion
2027-03-07
Completion
2027-03-07
First posted
2022-06-30
Last updated
2025-09-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05438563. Inclusion in this directory is not an endorsement.

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer (NCT05438563) · Clinical Trials Directory